~~<i id='32A70FA00C'><strike id='32A70FA00C'><tt id='32A70FA00C'><pre id='32A70FA00C'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：entertainment 2025-09-06 12:35:24 Page View：46816

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline
Next article： Apple is now the first public company to be valued at $3 trillion

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

How many hemophilia patients actually want gene therapy?

AdobeAsaboygrowingupwithhemophiliaA,NoahFrederickreservedtheendofhisannualcheckupstotalkaboutnewtech

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

FILE-PrinceHarryleavestheHighCourtaftergivingevidenceinLondon,Wednesday,June7,2023.PrinceHarryisseek